HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis

HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis

Leflunomide is used for the treatment of rheumatoid arthritis. Here, the authors show that effectiveness is limited in patients with higher levels of serum c-reactive protein (CRP). Using animal models, they show that higher CRP induces HIF1a expression, which in turn interferes with Leflunomide sig...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chao Liang, Jie Li, Cheng Lu, Duoli Xie, Jin Liu, Chuanxin Zhong, Xiaohao Wu, Rongchen Dai, Huarui Zhang, Daogang Guan, Baosheng Guo, Bing He, Fangfei Li, Xiaojuan He, Wandong Zhang, Bao-Ting Zhang, Ge Zhang, Aiping Lu
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/efd52d5facbd414982f94122c9661d92
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Leflunomide is used for the treatment of rheumatoid arthritis. Here, the authors show that effectiveness is limited in patients with higher levels of serum c-reactive protein (CRP). Using animal models, they show that higher CRP induces HIF1a expression, which in turn interferes with Leflunomide signalling, and that effectiveness of the drug is restored when HIF1a is pharmacologically inhibited.

Ejemplares similares